Technologies utilized to treat diseases like asthma, chronic obstructive pulmonary disease (COPD) and cystic fibrosis using pulmonary route of drug administration are identified as pulmonary drug delivery systems. Technological advancements have brought a lot of change in the way the pulmonary drug delivery systems work. Various technically advanced inhalation systems available in the market include soft mist inhalers, breath actuated inhalers, and inhalers with integrated drug dose counters.
Request a Sample Copy of the Report @ http://www.mrrse.com/sample/1096
The pulmonary drug delivery systems market has been broadly classified into three major segments namely metered dose inhalers (MDIs), dry powder inhalers (DPIs) and nebulizers. In 2012, the metered dose inhalers segment held the largest share (56.8%) of the total market, followed by the dry powder inhalers market. During the forecast period 2013 to 2019, the demand for metered dose inhalers is expected to be steady and the overall growth will be affected by the increasing demand for dry powder inhalers. The nebulizers market has been predicted as the fastest growing segment during the forecast period. On the basis of applications, the pulmonary drug delivery systems market has been segmented into asthma, COPD and cystic fibrosis.
Major growth drivers for the pulmonary drug delivery systems market during the forecast period include increasing prevalence of respiratory diseases like asthma and COPD, numerous benefits associated with these systems and technological advancements both in drug formulations and delivery systems. According to the World Health Organisation (WHO), asthma affects nearly 300 million people, while COPD affects around 210 million people worldwide. The WHO also estimated a steep increase in the number of asthma and COPD patients worldwide in the coming future due to ever changing lifestyle and tobacco smoking habits. Benefits associated with these systems such as non-invasive nature of administration, low drug dosage requirement, site-specific targeted delivery and fast onset of action will boost market growth in future. This growth will also depend upon the technological advancements like introduction of breath-actuated MDIs (Autohaler by 3M Health Care and Combivent Respimat a soft mist inhaler from Boehringer Ingelheim), use of enantiomers of certain drugs (for example, Levosalbutamol an active enantiomer of salbutamol), and integration of dose counters.
Inquiry on this report @ http://www.mrrse.com/enquiry/1096
Geographically, North America held the largest share in the global pulmonary drug delivery systems market in terms of revenue in 2012. Some major factors responsible for North America to hold the leading position include high prevalence of asthma and COPD in the U.S., well established reimbursement scenario and high level of awareness regarding the pulmonary drug delivery systems. Europe held the second largest share in 2012, followed by Asia-Pacific. The European market is expected to witness a low CAGR during the forecast period 2013 to 2019 due to reasons such as penetration by generic manufacturers and government austerity measures in key markets to reduce prices. In Asia-Pacific, the market is expected to grow under the influence of factors such as increasing incidences of respiratory diseases mainly due to high tobacco intake, increasing healthcare expenditure, and rise in level of awareness.
Read Complete Report with TOC @ http://www.mrrse.com/pulmonary-drug-delivery-systems
GlaxoSmithKline plc, Boehringer Ingelheim, AstraZeneca plc, Merck & Co., Inc., Philips Respironics, Inc., Omron Healthcare, Inc., Novartis AG, 3M Health Care, CareFusion Corporation and PARI Respiratory Equipment, Inc. are the major companies engaged in the development and commercialization of pulmonary drug delivery systems. All these players are consistently competing against each other to gain a competitive advantage over their rival companies.
90 State Street,
Albany NY – 12207